Stocks Hit Record on AI Rally | The China Show 6/1/2026

Key Concepts

• AI Trade & Supply Chain: The ongoing rally in tech stocks driven by AI infrastructure, including personal AI agents, AIPC (AI-enabled PCs), and data center expansion.
• Biotech Breakthroughs: The emergence of Chinese biotech firms (specifically Aesso) in global oncology, utilizing bi-specific agents and ADCs (Antibody-Drug Conjugates).
• Macro-Micro Divergence: The contrast between soft domestic Chinese economic data (PMI, retail sales) and the robust performance of the tech/export sectors.
• Geopolitical Shifts: The "softening" of US-China defense rhetoric (e.g., the Shangri-La Dialogue) and the focus on "asymmetrical warfare" and supply chain resilience.
• Market Dynamics: The role of retail investors in Taiwan and China as a dominant force in pricing, often outpacing foreign institutional demand.

---

1. Tech Sector & AI Momentum

• Lenovo: The stock has seen a parabolic rise (up 100% in May). Goldman Sachs upgraded its price target by 15%, citing Lenovo’s leadership in the AIPC trend and personal AI agent growth.
• Taiwanese Tech: Taiwan’s export projections are at their fastest growth rate in 45 years. The market is dominated by retail investors who are deeply integrated into the AI supply chain (circuit boards, substrates, and chip-to-board connectivity).
• Computex: The event is a focal point for guidance on whether the current AI earnings cycle is resilient and repeatable.
• SoftBank: The company’s pivot to building data centers in France has pushed its market cap above traditional industrial giants like Toyota, signaling a shift in investor preference toward "growth multipliers."

2. Healthcare & Biotech (Aesso Case Study)

• The Breakthrough: Aesso presented data at the ASCO (American Society of Clinical Oncology) conference showing their lung cancer drug extended patient survival from 24 to 28 months.
• Significance: This is the first time a China-originated innovative drug has reached the plenary session of ASCO.
• Commercial Potential: The lung cancer market is valued at $30–40 billion globally. Aesso’s drug, a bi-specific agent, is being positioned to challenge the current standard of care, Keytruda.
• Methodology: Aesso is running parallel trials (Harmony 6 in China, Harmony 3 globally) to derisk the process. CFO Bing Wang emphasized that the drug has already benefited over 70,000 patients in China, providing a consistent efficacy and safety profile.

3. Macroeconomic Indicators & China Policy

• PMI Data: Official manufacturing PMI hovered at 50.0, showing expansion but reflecting weakness in energy-intensive sectors due to Middle East conflicts and higher input costs.
• Trade Data: China’s imports surged by 25% YoY, driven by gold and semiconductors. While this creates a short-term trade deficit, it is viewed as a necessary investment for the AI boom and EV production.
• Fiscal Policy: Goldman Sachs notes that the Chinese government deliberately slowed bond issuance in Q2 after a strong Q1, suggesting a "counter-cyclical" approach to growth targets (4.5%–5%).

4. Geopolitical Developments

• Shangri-La Dialogue: US Defense Secretary Pete Hegseth avoided mentioning Taiwan in his speech, a historic shift in tone that Chinese state media interpreted as a recognition of China’s "governance wisdom."
• Asymmetrical Warfare: Defense officials from Malaysia and the Philippines discussed adopting "asymmetrical warfare" strategies to counter larger regional powers, emphasizing the need for supply chain security and intelligence sharing (e.g., the Philippines-Japan intelligence pact).
• Hanwa Aerospace: An explosion at a Hanwa Aerospace facility in Daejeon, South Korea, highlighted the risks associated with the rapid acceleration of defense production to meet global demand.

5. Notable Quotes

• Anthony Stevens (Bloomberg): "People are chasing upside on tech much more aggressively than they’re playing for downside on macro... You’re getting paid to be brave. You’re getting paid to dream about the future of tech."
• Bing Wang (CFO, Aesso): "Imitation is the best form of flattery... our lead especially in lung cancer is so significant that we believe our future market share will be very similar to that of [Keytruda] in the PD1 space."
• Carsten Breuer (German Chief of Defense): "We have all understood that we have to take care of our security on our own... but we can’t build up the needed capabilities that fast."

Synthesis/Conclusion

The market is currently defined by a "micro-wins-out" dynamic, where specific AI-related tech and innovative biotech breakthroughs are decoupling from broader macroeconomic concerns. While geopolitical tensions (Middle East, Taiwan) and soft domestic Chinese data present risks, the aggressive capital expenditure in AI infrastructure and the structural shift in China’s biotech industry are providing enough "alpha" to sustain investor confidence. The primary bottleneck moving forward is not just chip supply, but the physical infrastructure—power grids and data center capacity—required to sustain the AI revolution.